Aktienanalyse zu Kairos Pharma Ltd (KAPA)KAPAKairos Pharma Ltd

Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. Its therapy includes antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its portfolio consists of seven drug therapies consisting of peptide and small molecule cancer immunotherapeutics KROS 101, 102, 201, 301 and 401 and therapeutic agents ENV 105 and 205. KROS 101 is a small molecule that targets the glucocorticoid-induced tumor necrosis factor ligand-related (GITR) ligand, a signal for T cell growth to remove a checkpoint barrier to fight a host of cancers. KROS 201 is a T cell therapy activated by dendritic cells to treat glioblastoma, a deadly and common brain cancer. ENV 105 drug seeks to address unmet medical needs in large markets of prostate and lung cancers. It operates in the Healthcare sector.

Kairos Pharma Ltd (KAPA) is not a good buy right now due to its significant financial struggles and poor technical indicators. The stock is currently priced at $0.49, which is a staggering 90.31% down year-to-date and 92.38% down over the past year. Additionally, the RSI is at 35.563, indicating that the stock is nearing oversold territory, but this does not guarantee a rebound. The forward P/E ratio is 0, reflecting a lack of expected earnings growth, and the company has reported negative net income consistently, with a loss of $1,654,000 in Q1 2026. The main risk is the company's ongoing financial losses, with an EPS of -0.55 expected in the next earnings report, which could further depress the stock price.